Deucravacitinib (BMS-986165) for Pityriasis Rubra Pilaris

Summary

The purpose of this study is to evaluate the safety and effectiveness of Deucravacitinib (BMS-986165) in Pityriasis Rubra Pilaris as assessed by the change in Investigator Global Assessment (IGA), PASI- 50, 75, 90, DLQI, NRS itch, and Skindex-16 at week 24. To predict responses through the identification of unique biomarkers of PRP utilizing single-cell RNA sequencing.

Timeline

Start

2024-07-29

Primary completion

2025-09-02

Completion

2026-05-01

Drugs

Indications